References
Hamilton Sr. Esophagitis. In Phatology of the Gastrointestinal Tract. Second edition. Siu-Chun Ming, Harvey Goldman Editors. Williams and Wilkins. 1998; 20: 433-474.
Nason KS, Wichienkuer PP, Awais O, Schuchert MJ, Luketich JD, O’Rourke RW, et al. Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis. Arch Surg 2011; 146: 851-8.
Moore M, Afaneh C, Benhuri D, Antonacci C, Abelson J, Zarnegar R. Gastroesophageal reflux disease: A review of surgical decision making. World J Gastrointest Surg. 2016; 8: 77-83.
Ciriza-de-los-Ríos C. Barrett´s esophagus: a review. Rev Esp Enferm Dig 2010; 102: 257-269.
King A, MacDonald C, Orn C. Understanding gastro-oesophageal reflux disease: a patient-cluster analysis. Int J Clin Pract. 2008; 62: 1838-43.
Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004; 191: 95-105.
Rey E, Alvarez-Sánchez A, Rodríguez-Artalejo F, Moreno Elola-Olaso C, Almansa C, Díaz-Rubio M. Onset and disappearance rates of gastroesophageal reflux symptoms in the Spanish population, and their impact on quality of life. Rev Esp Enferm Dig. 2009; 101: 477-82.
Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol. 1988; 19: 942-8.
Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129: 1825-31.
Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014; 371: 836-45.
Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002; 123: 461-7.
Alcedo J, Ferrández A, Arenas J, Sopeña F, Ortego J, Sainz R, Lanas A. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus. 2009; 22: 239-48.
Sánchez Robles C, Santalla Peciña F, Retamero Orta MD. Barrett esophagus. An epidemiological study in an area of Spain. Rev Esp Enferm Dig. 1995; 87: 353-5.
Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am Gastroenterol 1999; 94:86-91.
Prateek S. The Worldwide Prevalence of Barrett’s Esophagus. World Gastroenterology News, 2001; 1: 22-25.
Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122: 26-33.
Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol. 2005; 162: 454-60.
Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008; 103: 788-97.
Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340: 825-31.
Flejou J F. WHO Classification of digestive tumors: the fourth edition. Ann Pathol 2011; 31: S27–31.
Riddell RH, Goldman H, Ransohoff DE, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical information. Hum Pathol 1983; 14: 931-68
Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GN, Vieth M. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006; 13: 1392-9.
Vahabzadeh B, Seetharam AB, Cook MB, Wani S, Rastogi A, Bansal A, Early DS, Sharma P. Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc. 2012; 75: 236-41.
Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012; 62: 118-28.
Dubecz A, Solymosi N, Stadlhuber RJ, et al. Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. J Gastrointest Surg 2014; 18: 124-129.
Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am 2015; 44: 203-231.
Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus:a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-49.
Gilbert EW, Luna RA, Harrison VL, et al. Barrett's esophagus: a review of the literature. J Gastrointest Surg 2011; 15: 708-18.
Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett´s adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640.
Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002; 95: 2096-102.
Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol 2005; 162: 1050-61.
Corley DA, Kubo A, Levin TR, et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009; 58: 182-8.
Instituto Nacional de Estadística. Ministerio de Sanidad, Servicios Sociales e Igualdad. Encuesta Nacional de Salud 2011-2012. http://www.ine.es/prensa/np770.pdf
Cook MB, Greenwood DC, Hardie LJ, et al. A systematic review and meta-analysis of the risk of increasing adiposity on Barrett´s esophagus. Am J Gastroenterol 2008; 103: 292-300.
Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872-878.
Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002; 11: 745-52.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
Veugelers PJ, Porter GA, Guernsey DL, et al. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006; 19: 321-28.
Thrift AP, Cook MB, Vaughan TL, et al. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol 2014; 109: 1586-94.
Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012; 142: 744-53.
Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013; 11: 1430-6.
Pohl H, Pech O, Arash H, et al. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut. 2016; 65: 196-201.
Van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008; 27: 316-20.
Portale G, Peters JH, Hsieh CC, et al. Esophageal adenocarcinoma in patients or = 50 years old: delayed diagnosis and advanced disease at presentation. Am Surg 2004; 70: 954-8.